非瑟酮减缓老年脓毒症进展(STOP-Sepsis):多中心、随机、适应性分配临床试验的研究方案
本研究为多中心、随机、双盲、适应性分配的2期临床试验,计划纳入220例年龄>65岁的脓毒症老年患者,随机接受非瑟酮单次口服20 mg/kg、非瑟酮两次口服20 mg/kg间隔1天或安慰剂,主要结局为入组7天时心血管、呼吸和肾脏序贯器官衰竭评估评分复合值的变化。
要点
- 非瑟酮单次20 mg/kg或两次20 mg/kg间隔1天口服,对照为安慰剂。
- 主要结局为入组7天时心血管、呼吸和肾脏序贯器官衰竭评估评分复合值的变化。
- 次要结局包括7天衰老CD3+细胞定量及28天无器官衰竭天数、ICU天数及全因死亡率。
核心结论
- 该2期试验旨在评估非瑟酮预防老年脓毒症患者临床恶化的疗效,并测量该药对衰老免疫细胞流行率的影响,作者打算用其结果指导更大规模3期研究的设计。
研究设计与样本
- 多中心、随机、双盲、适应性分配的2期临床试验,计划纳入并随机220例年龄>65岁且临床诊断为脓毒症的老年患者。
关键数值与推荐
- 非瑟酮单次口服剂量为20 mg/kg。
- 非瑟酮两次口服剂量各为20 mg/kg,间隔1天。
- 主要结局为入组7天时心血管、呼吸和肾脏序贯器官衰竭评估评分复合值的变化。
- 次要结局包括7天时衰老CD3+细胞定量,以及28天无器官衰竭天数、重症监护室天数和全因死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Senescent immune cells exhibit altered gene expression and resistance to apoptosis. The prevalence of these cells increases with age and emerging data implicate senescence-associated maladaptive signaling as a potential contributor to sepsis and septic shock. The senolytic drug fisetin promotes clearance of senescent cells and is hypothesized to mitigate septic responses to infection. METHODS: We are conducting a multi-center, randomized, double-blinded, adaptive allocation phase 2 clinical trial to assess the efficacy of the senolytic drug fisetin in preventing clinical deterioration of elderly patients diagnosed with sepsis. We intend to enroll and randomize 220 elderly patients (age > 65) with the clinical diagnosis of sepsis to receive either fisetin as a single oral dose of 20 mg/kg, fisetin in two oral doses of 20 mg/kg each spaced 1 day apart, or placebo. The primary outcome will be changed in the composite of cardiovascular, respiratory, and renal sequential organ failure assessment scores at 7 days from enrollment. Secondary outcomes include quantification of senescent CD3 + cells at 7 days, and 28-day assessments of organ failure-free days, days in an intensive care unit, and all-cause mortality. DISCUSSION: This multi-center, randomized, double-blinded trial will assess the efficacy of fisetin in preventing clinical deterioration in elderly patients with sepsis and measure the effects of this drug on the prevalence of senescent immune cells. We intend that the results of this phase 2 trial will inform the design of a larger phase 3 study. TRIAL REGISTRATION: This trial is registered to ClinicalTrials.gov under identifier NCT05758246, first posted on March 7, 2023.
引用
- Silva M, Wacker DA, Driver BE, et al. Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial. Trials. 2024. PMID: 39434114. doi:10.1186/s13063-024-08474-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。